clinical trials

Izana starts proof-of-concept trial for spinal arthritis drug
Izana starts proof-of-concept trial for spinal arthritis drug
Fierce Biotech
Izana
clinical trials
namilumab
ankylosing spondylitis
Flag link:
Gemphire's lead drug worsened disease, investigators conclude in ending trial
Gemphire's lead drug worsened disease, investigators conclude in ending trial
Biopharma Dive
Gemphire Therapeutics
clinical trials
NASH
Flag link:
Ampio Pharma craters on FDA setback but plans to fight back
Ampio Pharma craters on FDA setback but plans to fight back
Fierce Biotech
Ampio Pharmaceuticals
FDA
clinical trials
osteoarthritis
Ampion
Flag link:
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
ASCO and Friends of Cancer Research Draft 5 Guidances for FDA
RAPS.org
ASCO
FDA
cancer
oncology
clinical trials
Friends of Cancer Research
Flag link:
Far-fetched fictional pharma trial anchors new Netflix series ‘Maniac’
Far-fetched fictional pharma trial anchors new Netflix series ‘Maniac’
Fierce Pharma
clinical trials
Flag link:
RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study
RegenxBio rally fades fast after biotech reports setbacks, hospitalization in gene therapy study
Endpoints
Regenxbio
gene therapy
RGX-501
clinical trials
HoFH
Flag link:
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
Clovis Starts Ph III Trial with Combination of Rubraca and Opdivo in Advanced Ovarian Cancer
CP Wire
Clovis Oncology
clinical trials
Bristol-Myers Squibb
Opdivo
ovarian cancer
Flag link:
Here's Why Acceleron Pharma Inc. Lost 10.2% in July
Here's Why Acceleron Pharma Inc. Lost 10.2% in July
Yahoo/Motley Fool
Acceleron
clinical trials
luspatercept
Flag link:
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Xtalks
Mallinckrodt
MNK-1411
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Anthem Taps Artificial Intelligence Space With Allergy Research Trial
Anthem Taps Artificial Intelligence Space With Allergy Research Trial
Forbes
Anthem
doc.ai
clinical trials
artificial intelligence
allergies
Flag link:
Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s
Teva’s one-time blockbuster-to-be — and now recurring embarrassment — laquinimod fails yet again, this time for Huntington’s
Endpoints
Teva Pharmaceutical
Active Biotech
Huntington's disease
clinical trials
laquinimod
Flag link:
Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Otsuka’s $886M-plus drug just flopped in its first crucial PhIII trial for frontline AML
Endpoints
Otsuka
SGI-110
clinical trials
AML
Flag link:
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
Fortune
Biogen
Eisai
BAN2401
clinical trials
Alzheimer's disease
Flag link:
Constrained peptides’ time to shine?
Constrained peptides’ time to shine?
Nature
drug development
clinical trials
R&D
contstrained peptides
Flag link:
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
RedHill’s RHB-104 hits primary endpoint in Crohn’s phase 3
Fierce Biotech
Redhill Biopharma
clinical trials
Crohn's Disease
RHB-104
Flag link:
Sienna slumps as acne asset flunks phase 3 trials
Sienna slumps as acne asset flunks phase 3 trials
Fierce Biotech
Sienna Biopharmaceuticals
clinical trials
acne
SNA-001
Flag link:
Viagra Clinical Trial of Pregnant Women Ends After 11 Babies Die as a Result of Lung Problems
Viagra Clinical Trial of Pregnant Women Ends After 11 Babies Die as a Result of Lung Problems
Xtalks
clinical trials
Viagra
pregnancy
drug safety
generics
Flag link:
Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down
Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down
Endpoints
Biogen
Eisai
Alzheimer's disease
BAN2401
clinical trials
Flag link:
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Endpoints
Merck
Keytruda
clinical trials
squamous cell carcinoma of the head and neck
Flag link:
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Can Celgene's latest Revlimid win reverse the company's bad-news streak?
Fierce Pharma
Celgene
Revlimid
clinical trials
Roche
Rituxan
non-Hodgkin lymphoma
Flag link:

Pages